echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's Acute Leukemia Drug Ogaituzumab for Injection Approved in China

    Pfizer's Acute Leukemia Drug Ogaituzumab for Injection Approved in China

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 22, Pfizer announced that the National Medical Products Administration of China has approved Bebossa® (Ogaituzumab for injection) for relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R /R B-ALL) adult patients, this is also the world's first approved antibody-drug conjugate (ADC) for the treatment of R/R B-ALL


    Leukemia is a common tumor of the blood and lymphatic system.


    ADC drugs have changed the treatment status of adult R/R ALL patients


    Note: The original text has been deleted

    Reference materials:

    1.


    2.


    3.


    4.


    5.


    6.


    7.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.